Table 1 Population specific estimates of the transmissibility of MERS-CoV in camels

From: Modelling transmission of Middle East respiratory syndrome coronavirus in camel populations and the potential impact of animal vaccination

     

R0

    

FoI,λ

Relative infectiousness of reinfections

 

Dataset

Seroprevalence (%)

Test

Model 4:

1%

50%

Africa

Egypt53

<2 yrs 37% (n = 595)

≥2 yrs 82% (n = 1946)

MN

0.5 (0.4, 0.7)

4.2 (3.7, 5.1)

1.9 (1.8, 2.1)

Egypt16

<2 yrs 16% (n = 447)

≥2 yrs 84% (n = 1586)

MN

0.5 (0.4, 0.6)

4.0 (3.5, 4.7)

1.9 (1.8, 2.0)

Ethiopia54

1–≤2 yrs 93% (n = 31)

2–13 yrs 97% (n = 157)

PM

2.6 (1.5, 9.7)

14.9 (9.6, 44.0)

3.0 (2.6, 4.9)

Kenya55

<6 m 39% (n = 61)

6m–2yrs 21% (n = 80)

>2 yrs 61% (n = 194)

PM

0.2 (0.2, 0.4)

2.6 (2.1, 3.5)

1.7 (1.4, 1.8)

Kenya56

1–4 yrs 73% (n = 285)

4–6 yrs 98% (n = 116)

6 yrs 98% (n = 476)

ELISA

1.0 (0.8, 2.3)

6.8 (5.5, 13.4)

2.3 (2.2, 2.9)

Kenya57

<4 yrs 36% (n = 319)

>4 < 7 yrs 59% (n = 70)

>7 yrs 82% (n = 760)

ELISA

0.3 (0.2, 0.4)

2.9 (2.5, 3.7)

1.7 (1.6, 1.9)

Senegal16

<2 yrs 29% (n = 17)

≥2 yrs 69% (n = 181)

MN

0.3 (0.2, 0.6)

2.9 (2.3, 4.6)

1.7 (1.5, 2.0)

Tunisia16

<2 yrs 100% (n = 28)

≥2 yrs 87% (n = 754)

MN

0.8 (0.6, 2.2)

5.8 (4.6, 12.8)

2.2 (2.0, 2.8)

Tunisia54

<2 yrs 30% (n = 46)

≥2 yrs 54% (n = 158)

PM

0.2 (0.1, 0.3)

2.2 (1.8, 3.1)

1.5 (1.3, 1.7)

Uganda16

<2 yrs 52% (n = 150)

≥2 yrs 66% (n = 350)

MN

0.3 (0.2, 0.6)

3.2 (2.6, 4.5)

1.8 (1.7, 2.0)

West Asia

Iraq16

<2 yrs 33% (n = 6)

≥2 yrs 57% (n = 21)

MN

0.2 (0.1, 7.5)

2.6 (1.7, 35.3)

1.7 (1.3, 4.3)

Iraq58

<2 yrs 89% (n = 44)

2–4 yrs 81% (n = 58)

>4 yrs 86% (n = 78)

ELISA

1.8 (0.9, 9.4)

10.6 (6.4, 43.0)

2.7 (2.3, 4.8)

Jordan16

<2 yrs 50% (n = 82)

≥2 yrs 92% (n = 222)

MN

1.0 (0.7, 2.4)

6.9 (5.0, 13.8)

2.3 (2.1, 2.9)

Jordan37

≤2 yrs 74% (n = 31)

>2 yrs 100% (n = 14)

ELISA

2.6 (1.2, 9.5)

14.8 (7.8, 43.1)

3.0 (2.4, 4.8)

KSA38 1992-2010

≤2 yrs 55% (n = 104)

>2 yrs 95% (n = 98)

ELISA

1.9 (1.1, 7.5)

10.9 (7.2, 36.3)

2.7 (2.4, 4.4)

KSA38 2013

≤2 yrs 73% (n = 77)

>2 yrs 93% (n = 187)

ELISA

1.2 (0.7, 2.8)

7.5 (5.3, 15.7)

2.4 (2.1, 3.0)

KSA17

1–2 yrs 93% (n = 71)

3–5 yrs 78% (n = 100)

ELISA

2.3 (1.2, 9.5)

13.2 (7.5, 43.1)

2.9 (2.4, 4.8)

KSA26

<1 yr 72% (n = 65)

1–3 yrs 95% (n = 106)

4–5 yrs 97% (n = 76)

>5 yrs 92% (n = 63)

ppNT

3.2 (1.8, 9.1)

16.6 (10.4, 41.7)

3.1 (2.6, 4.7)

KSA16

<2 yrs 82% (n = 11)

≥2 yrs 82 % (n = 211)

MN

0.6 (0.4, 2.2)

4.5 (3.4, 12.6)

2.0 (1.8, 2.8)

UAE11

≤1 yr 85% (n = 108)

2–4 yrs 97% (n = 340)

>4 yrs 96% (n = 310)

ELISA

7.1 (3.5, 9.8)

33.7 (18.5, 44.5)

4.2 (3.2, 4.9)

South Asia

Bangladesh59

<2 yrs 9% (n = 11)

≥2 yrs 36% (n = 44)

ppNT

0.1 (0.0, 0.3)

1.7 (1.3, 3.2)

1.3 (1.1, 1.8)

Pakistan30

≤2 yrs 29% (n = 89)

2.1–5 yrs 30% (n = 208)

5.1–10 yrs 51% (n = 180)

>10 yrs 49% (n = 88)

ELISA

0.1 (0.1, 0.2)

1.9 (1.7, 2.3)

1.4 (1.3, 1.5)

Pakistan60

≤3 yrs 58% (n = 177)

3.1–10 yrs 79% (n = 712)

>10 yrs 81% (n = 161)

ELISA then MN

0.4 (0.3, 0.6)

3.9 (3.3, 4.9)

1.9 (1.8, 2.1)

Global

Rate of waning mAbs, ω

  

4.9 (3.2, 9.6)

  

Rate of waning Abs, σ

  

0.06 (0.03, 0.11)

  

Overdispersion, k

  

2.5 (2.0, 3.2)

  
  1. MN microneutralisation test, ppNT pseudo particle neutralisation test, PM protein micro-array, ELISA Enzyme linked immunosorbent assay.